banner
 
bar

program

slides
bar
 
 

Optimizing Glycemic Control
in Type 2 Diabetes

WebCAST

Webcast CE Disclosure

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

1.0 hours

Course Overview

In this web-based program, nurse practitioners and other health care professionals will learn how recent advances in basic and clinical research have helped to advance the understanding of advances in managing patients with Type 2 diabetes.

Release Date

September 25, 2014

Expiration Date

September 25, 2016

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CE credit for this activity. During the period September 25, 2014 through September 25, 2016, participants must 1) Complete the free AANP registration process; 2) read the learning objectives and faculty disclosures; 3) study the educational activity, and are expected to view both segments totaling 1.0 hours to successfully complete the activity and earn AANP credit; 4) register and complete the evaluation form and post-test; 5) score 70% on the post-test; and 5) print out your CE certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CE-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from AstraZeneca

Program Faculty and Disclosure

JANE KAPUSTIN, PHD, CRNP, BC-ADM, FAANP, FAAN
Professor
Assistant Dean for the Master's and DNP Programs
University of Maryland School of Nursing
Baltimore, MD

Nothing to disclose


JUAN P. FRIAS, MD, FACE
Assistant Clinical Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, CA

Research Grants: Sanofi, Eli Lilly, Novo Nordisk, Merck, BMS, Pfizer, Boehringer Ingelheim, Abbvie, Allergan, Janssen

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.

Educational Objectives

Upon completion of the program, participants will be able to:

  • Describe the epidemiology, scope of problem, risk assessment, target goals, and multiple interventions that currently are deployed for T2D and that have been shown to be helpful for glycemic regulation in T2D; and, the impact of successful glycemic management of T2D on microvascular and macrovascular complications; and their impact on comprehensive cardiometabolic management of patients with T2D
  • Understand advances in therapeutic strategies based on new mechanisms, involving SGLT2 inhibitors (encoded by the SLC5A2 gene), and their impact on glucose homeostasis; and, the effects these agents may have on cardiometabolic markers, including lipids, insulin resistance, intra-renal hemodynamics, inflammatory pathways, HA1c levels, glucose levels, and microvascular/macrovascular disease
  • Examine the mechanisms underlying, and the potential clinical implications of, SGLT2 inhibition and its potential for shifting the glucose “reabsorption/excretion” threshold to the left, thereby introducing a physiological basis for reducing plasma glucose in patients with T2D; and, in which patient populations and for which clinical profiles, such mechanisms and metabolic effects may be of special benefit
  • Apply landmark trials, national guidelines from the EASD/ADA 2012 Guidelines and AACE to the clinical challenge of multidimensional therapeutic interventions for T2D; and how emerging therapies aimed at inhibiting glucose reabsorption in the kidney can play a role as monotherapy, or in other multi-drug combinations with established agents for diabetes, for managing patients with T2D and optimizing HA1c target goal attainment

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CE certificate.

Privacy Policy

When you participate in a CE activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CE activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CE activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CE activities that CEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2014 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC


bar

program

slides
bar

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

ACC/AHA/ESC Guidelines
ACTIVE-A
anticoagulation
Antiplatelet
Antithrombotic
Apixaban
ARISTOTLE
aspirin
ATHENA
Atrial Fibrillation

Stroke
AVERROES
cardiomyopathy
Cardioversion
CHADS2
CHADS-VASC?
clopidogrel
Dabigatran
Dronedarone

 

Edoxaban
ESC AF
Factor Xa Inhibitor
HAS-BLED
Hyperthyroidism
Intracerebral Hemorrhage
Myocardial infarction
myocarditis
Pericarditis
Pulmonary embolism

RE-LY Trial
rhythm control
Rivaroxaban
ROCKET-AF
SPAF-I
supraventricular
tachyarrhythmia
Valvular Atrial Fibrillation
VKA
Warfarin